Once-weekly compared with three-times-weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic-equivalence study

American Journal of Kidney Diseases

Volumn 40, Issue 1, 2002, Pages 119-125

  Locatelli, Francesco ^a   Baldamus, Conrad A ^a   Villa, Giuseppe ^a   Ganea, Alexandru ^a   Martín de Francisco, Angel L ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Dosage regimen; Epoetin ; Equivalence study; Renal anemia; Subcutaneous (SC)

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0036283349     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.33920     Document Type: Article

References (23)

1. DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
2. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000
3. European best practice guidelines for the management of anaemia in patients with chronic renal failure
4. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
5. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
6. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
7. Hematocrit level and associated mortality in hemodialysis patients
8. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - A retrospective study
9. Hematocrit levels and hospitalization risks in hemodialysis patients
10. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease
11. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
12. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
13. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
14. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
15. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients?
16. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients
17. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
18. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
19. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error
20. Kinetic modelling in hemodialysis
21. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products
22. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability